Skip to content
Aminoscope
← Research
GLP-1

Contrave vs Wegovy: the weight-loss gap is large

Both are approved weight-loss drugs, but Wegovy (a GLP-1 injection) produced ~14.9% weight loss versus ~6.1% for the oral Contrave — about 2.5 times more. Contrave's niche is being needle-free.

Julian Roth6 min read
Wegovy (GLP-1 injection) produced far more weight loss than Contrave (oral appetite pill)−14.9%Wegovyweekly injection−6.1%Contravedaily pillGLP-1 INJECTION VS APPETITE PILL · 14.9% VS 6.1%

Contrave versus Wegovy is a real choice between two approved weight-loss medications — not the same molecule in different packaging, but genuinely different drugs that work in different ways and produce very different results. The honest comparison comes down to effectiveness versus form.

Two different mechanisms

Contrave combines two old drugs: naltrexone (an opioid-receptor blocker) and bupropion (an antidepressant). Together they act on the brain’s appetite and food-rewardcircuits, taken as a pill twice daily. Wegovy is semaglutide, a GLP-1 receptor agonist — a once-weekly injection that slows gastric emptying and powerfully reduces appetite through gut-hormone signaling. Different targets, very different potency.

The weight-loss gap

The effectiveness difference is large. In its pivotal COR-I trial, Contrave (at the approved dose) produced about 6.1% weight loss versus 1.3% on placebo.[1] Wegovy, in the STEP 1 trial, produced about 14.9% weight loss versus 2.4% on placebo.[2]That’s roughly 2.5 times more weight loss with Wegovy — a clinically major difference, not a rounding error.

  • Wegovy (semaglutide 2.4 mg)14.9%
  • Contrave (naltrexone-bupropion)6.1%
Mean weight loss in each drug's pivotal trial — Wegovy (STEP 1) versus Contrave (COR-I). Units: % body weight. STEP 1 (PMID 33567185); COR-I (PMID 20673995)
Wegovy wins decisively on weight loss; Contrave's advantages are being oral and targeting reward-driven eating.
Wegovy (semaglutide)Contrave (naltrexone-bupropion)
TypeGLP-1 injectionOral combination pill
MechanismGut-hormone appetite signalingAppetite + food-reward circuits
DosingOnce weeklyTwice daily
Weight loss (trial)~14.9%~6.1%
Needle-free?NoYes
Wegovy wins decisively on weight loss; Contrave's advantages are being oral and targeting reward-driven eating. STEP 1 (PMID 33567185); COR-I (PMID 20673995)

The honest verdict

For maximum weight loss, this isn’t close: Wegovy produced roughly 2.5 times the weight loss of Contrave in their respective trials.[1][2] If effectiveness is the priority and a weekly injection is acceptable, Wegovy is the stronger choice. Contrave is the reasonable pick for people who need an oral option, have reward-driven eating, or face GLP-1 coverage barriers. To compare Wegovy against the tirzepatide brand, see Zepbound vs Wegovy; for the older injectable, Wegovy vs Saxenda; and for cost and access, our Wegovy cost guide and provider comparison.

Reviewed against primary sources by the Aminoscope desk

Sources

  1. [1] Greenway FL, Fujioka K, Plodkowski RA, et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. PMID 20673995
  2. [2] Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185

Related tool

GLP-1 weight-loss comparison

See semaglutide, tirzepatide, retatrutide and the pipeline ranked by mean trial weight loss — every figure traced to its source.

More in GLP-1